Device Tissue Diagnostics

Benchmark Special Stains Wash II

Payments companies reported to CMS as associated with Benchmark Special Stains Wash II. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$7,341associated payments (2023-2025)
72clinicians with associated payments
1company reporting

By year

2023 $7,341

Payments reported as associated with Benchmark Special Stains Wash II, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anatomic Pathology & Clinical Pathology $4,980
Anatomic Pathology $1,869
Clinical Pathology/Laboratory Medicine $292
Clinical Pathology $48.39
Internal Medicine $27.13
Cytopathology $24.86

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Benchmark Special Stains Wash II

These are the largest totals companies reported as associated with Benchmark Special Stains Wash II. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Shirley Shiller Nashville, TN Anatomic Pathology & Clinical Pathology $2,925.00
Sarah Gradecki Charlottesville, VA Anatomic Pathology $1,755.00
Yorke Young Knoxville, TN Anatomic Pathology & Clinical Pathology $381.60
Kent Newsom Columbia, SC Anatomic Pathology & Clinical Pathology $148.30
Bryan Dangott Jacksonville, FL Clinical Pathology/Laboratory Medicine $131.80
David Mcclintock Ann Arbor, MI Anatomic Pathology & Clinical Pathology $131.79
Toby Cornish Milwaukee, WI Anatomic Pathology & Clinical Pathology $131.79
Lemuel Gorden Montgomery, AL $53.88
Nella Fernandez Montgomery, AL Clinical Pathology/Laboratory Medicine $53.88
Steven Mann Asheville, NC Clinical Pathology/Laboratory Medicine $53.88

Prescribed Benchmark Special Stains Wash II?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.